NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
163 trialsNCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03570892 2026-04-08
BELINDA
Novartis
Phase 3 Completed
NCT04231448 2026-04-08
DEB
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT04628494 2026-04-08
EPCORE DLBCL-1
Genmab
Phase 3 Active not recruiting
NCT06508658 2026-04-08
EPCORE DLBCL-4
Genmab
Phase 3 Active not recruiting
NCT07226752 2026-04-08
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Genmab
Phase 3 Active not recruiting
NCT04408638 2026-04-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT04824092 2026-04-01
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT07493109 2026-03-25
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
The First Hospital of Jilin University
Phase 3 Recruiting
NCT04384484 2026-03-24
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting
NCT04404283 2026-03-17
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT07188558 2026-03-04
PiNACLE-H2H
Lyell Immunopharma, Inc.
Phase 3 Recruiting
NCT04214444 2026-02-12
EVAPOR
University Hospital, Tours
Phase 3 Completed
NCT03274492 2026-02-06
POLARIX
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06091865 2026-02-05
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT07348575 2026-01-16
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University
Phase 3 Enrolling by invitation
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT04182204 2025-12-22
POLARGO
Hoffmann-La Roche
Phase 3 Completed
NCT05429268 2025-12-10
firmMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT03391466 2025-12-01
ZUMA-7
Gilead Sciences
Phase 3 Completed
NCT06929624 2025-11-18
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT04833114 2025-09-30
Pola-R-ICE
GWT-TUD GmbH
Phase 3 Active not recruiting
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT06792253 2025-01-24
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 3 Recruiting
NCT03263026 2025-01-23
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1â„¢
Denovo Biopharma LLC
Phase 3 Completed
NCT05578976 2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3 Active not recruiting
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT04332822 2024-09-19
POLAR BEAR
Nordic Lymphoma Group
Phase 3 Recruiting
NCT06573645 2024-08-27
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06522555 2024-08-05
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital
Phase 3 Recruiting
NCT03213977 2024-03-27
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Fujian Medical University
Phase 3 Unknown
NCT03650933 2024-02-20
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Nanjing Yoko Biomedical Co., Ltd.
Phase 3 Unknown
NCT05234684 2024-02-07
BELIEVE-01
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT04361279 2023-12-27
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Institute Of Biological Products
Phase 3 Completed
NCT02617485 2023-10-25
MADILYM
Mabion SA
Phase 3 Completed
NCT05820841 2023-08-31
ARCHED
Universität des Saarlandes
Phase 3 Recruiting
NCT00078949 2023-08-23
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Phase 3 Completed
NCT05020392 2023-07-25
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Unknown
NCT02285062 2023-06-22
ROBUST
Celgene
Phase 3 Completed
NCT05018520 2023-05-31
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Ruijin Hospital
Phase 3 Unknown
NCT05179733 2023-05-23
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Phase 3 Unknown
NCT03372837 2023-04-18
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
Phase 3 Completed
NCT05351346 2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3 Recruiting
NCT04236141 2023-03-03
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Hoffmann-La Roche
Phase 3 Terminated